India's Glenmark To Study Potential COVID-19 Drug Combination
Glenmark said it would conduct clinical trials in India of just favipiravir as a potential treatment for COVID-19.
Photo Credit :
1590472311_N0R0pU_2020_05_26T052912Z_1_LYNXMPEG4P09Y_RTROPTP_4_HEALTH_CORONAVIRUS_INDIA.JPG
![]()
Glenmark Pharmaceuticals Ltd said on Tuesday it will begin a new clinical trial in India to test a combination of two anti-viral drugs - favipiravir and umifenovir - as a potential COVID-19 treatment.
The study will look to enroll 158 hospitalized patients of moderate COVID-19 in India, the company added.
Last month, Glenmark said it would conduct clinical trials in India of just favipiravir as a potential treatment for COVID-19.
(Reuters)